Introduction
The aim of the treatment of chronic stable angina pectoris is to improve the prognosis by preventing myocardial infarction and death, and to minimize or abolish symptoms [1, 2] . It has been shown that more than 50% of treated patients report a poor or fair quality of life [3] , thus emphasizing the need for careful monitoring of symptom evolution under treatment. Despite the increasing popularity of interventional procedures such as coronary artery bypass grafting and angioplasty, non-invasive treatment remains the mainstay of antianginal management [3, 4] . Because long-term use of b-blockers has been shown to reduce mortality following myocardial infarction, recent guidelines on the treatment of stable angina recommend the use of b-blockers as first-line agents [1, 2] . However, no single class of therapy has been proven to be prognostically superior in the treatment of chronic stable angina [5] .
The use of combination therapy is often considered to be the most rational approach to the treatment of stable angina because of somewhat different mechanisms of action of the various classes of antianginal drugs [4] . However, not all of the published trials showed a greater efficacy of combined therapies over monotherapies and according to the Task Force of the European Society of Cardiology, when a single agent is ineffective, it is probably best to evaluate an alternative single drug before starting combination treatment [1] . Therefore, we performed a meta-analysis of randomized trials that directly compared combined treatment with monotherapy in order to determine the relative efficacy of combined treatment and monotherapy in patients with stable angina.
Methods

Data sources
Clinical studies published in English between 1980 and December 1999 were identified by a Medline search, references from review articles on the medical treatment of stable angina and the Cochrane library. Search criteria were (1) stable angina pectoris, (2) the publication type (randomized clinical trial or controlled clinical trial) and (3) human use. Finally, bibliographies of identified trials were reviewed to locate other relevant studies.
Study selection
Trials were included when the enrolled patients had a history of stable angina and a direct comparison between monotherapy and combined therapy was available. Studies with a duration of less than 1 week were excluded. Criteria for selection of treatment were double-blind randomized trials where patients were treated by a combination of two drugs of two different classes among b-blockers, calcium antagonists or long-acting nitrates in comparison with monotherapy with one of the above.
Outcome measures
Measures of antianginal efficacy were examined. Measures of antianginal efficacy were those evaluated on exercise testing performed on a treadmill or an upright bicycle. No data were available on clinical outcome such as death or myocardial infarction, except in one trial [6] . Clinical data in the articles were not always available and not consistently reported (heterogeneous reporting in the number of angina episodes or short-acting nitrate consumption). Therefore, it was decided to exclude clinical parameters from the meta-analysis. Thus, the metaanalysis was restricted to the exercise-test parameters: total duration of exercise, time to onset of pain and time to 1 mm ST-segment depression. Not enough data were available to allow an estimation of the difference in the rate-pressure product.
Tolerance data were secondary criteria for this analysis. However, not enough data were available in the selected articles to allow a comparison on safety data.
Data extraction
Full texts of all the retrieved publications were assessed by a cardiologist who extracted the data from each article. Then the selection of the articles was performed by the cardiologist and a clinical statistician. The exercise-test data entry was double-checked.
Statistical analysis
Only one trial comparing long-acting nitrates in monotherapy or in combination fulfilled the selection criteria [7] . Therefore, the meta-analysis could be conducted only on b-blockers and calcium antagonists. Two separate analyses were performed, one for the comparison of bblocker monotherapies to their combination with a calcium antagonist (BB þ CA) and one for the comparison of calcium antagonist monotherapies to their combination with a b-blocker (CA þ BB). Trials that compared a b-blocker to a calcium antagonist and to their combination were included in both BB þ CA and CA þ BB.
Trials that compared several doses of a drug to a combination were included as many times as the number of tested doses.
SEMs were converted to SDs. The absolute difference and the percentage of the difference of combined therapy to monotherapy were estimated for each trial and for all the trials together.
The standardized mean differences were estimated following Hedges' method [8] that remains adapted for small sample sizes. Unbiased standardized mean differences and their 95% confidence intervals (CIs) were estimated for each trial and for all the studies together. A difference was considered statistically significant when the zero value was not included in the 95% CI. These results are displayed in Figures 1-3 .
An overall heterogeneity test was performed for each exercise-test parameter [9] . In order to differentiate 'peak' and 'trough' effects, secondary analyses were performed independently on two subgroups identified according to the time of exercising: within or later than 6 h following drug intake.
Secondary analyses were also performed independently on cross-over and parallel trials and on short-and long-acting calcium antagonists.
The percentage of patients with no angina and the percentage of patients without 1 mm ST-segment depression at the end of the trial were compared using Mantel-Haenzel adjusted w-square.
Results
Selected studies A total of 83 articles were identified. Finally, 23 trials were selected; this selection is graphically represented in Figure  4 , as recommended by the QUOROM consensus guidelines [10] . Only one trial comparing long-acting nitrates in monotherapy or in combination fulfilled our selection criteria [7] . The remaining 22 articles (26.5%), comparing the combination of a b-blocker with a calcium antagonist were abstracted and included in the analysis (Table 1) .
Eleven trials compared a b-blocker monotherapy to a combination of this b-blocker and a calcium antagonist [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] : three parallel-design and eight cross-over trials. One cross-over trial compared atenolol to its combination with either nisoldipine or nifedipine [22] . This trial was the only one with a comparison 2 h and 12 h after drug intake. Ten trials [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] compared a b-blocker, a calcium antagonist and their combination (four parallel-design and six cross-over trials). One out of these 10 trials tested two different doses of diltiazem [26] .
Ten trials [11] [12] [13] [14] [15] [16] 21, 22, 31, 32] specified that two exercise tests (ETTs) at least have to be performed before randomization. However, the reproducibility required was detailed in only four articles: total exercise duration of two different ETTs differing by 2 min or less [15] , 15% or less [31, 32] and 20% or less [21] . Five trials [13, 14, 23, 27, 31] included no mention about documented coronary angiography or documented history of myocardial infarction while in five trials [16, 17, 20, 22, 28] documented coronary angiography or documented history of myocardial infarction were criteria of inclusion. In one trial [25] coronary angiography was performed in only one patient.
All the selected trials were included in BB þ CA and 10 trials [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] in CA þ BB ( Table 2) . Two trials compared several doses of a drug to a combination and were included as many times as the number of tested doses [22, 26] . The mean duration of the trials was less than 1 month (Table 3) .
No overall heterogeneity test was statistically significant.
Comparison of a b-blocker to its combination with a calcium antagonist (BB þ CA)
Time to 1 mm ST-segment depression
The time to 1 mm ST-segment depression was available in 630 patients treated by a monotherapy and 615 patients receiving combined treatment. The time to 1 mm STsegment depression was 8% (33 s, P o 0.001) higher with the combined therapy. A graphical display is shown in Figure 1 . There was a statistically significant difference of 9% (43 s, P o 0.001) at peak while the difference of 3% (10 s, P ¼ 0.21) at trough was not statistically significant. Flow diagram of the selection of trials to be included in the metaanalysis. CT, controlled trial; RCT, randomized controlled trial. Adapted with permission [10] .
Total exercise duration
An estimation of total exercise duration was available for 818 patients receiving monotherapy and 796 patients receiving combined therapy. The adjusted difference in total exercise duration was 5% (23 s, P ¼ 0.002). between the two groups, in favour of the combined therapy. A graphical display of the mean differences estimated according to Hedges' method with the corresponding 95% CI is shown in Figure 2 . There was a insignificant difference at peak (5%, 29 s, P ¼ 0.21) and no difference at trough (1%, 4 s, P ¼ 0.14).
Time to onset of pain A significant increase in the time to onset of pain was shown with the combined therapy compared to a b-blocker alone (Fig. 3) . The difference in time to onset of pain was 12% (42 s, P o 0.001). The difference was significant in the analysis of the seven comparisons with an exercise test performed within 6 h following drug intake (þ8%, þ38 s, P ¼ 0.039). No statistical difference was shown after 6 h (0%, -4 s, P ¼ 0.65).
Similar results were noted when short-and long-acting preparations of calcium antagonists were evaluated separately, except for 1 mm ST-segment depression where the difference was not statistically significant in the two trials with the combination of short-acting calcium antagonists (þ9%, 45 s, P ¼ 0.085) [27, 29] .
Similar results were noted for the secondary analysis performed independently on cross-over and parallel trials, except for total duration of exercise test where the difference was not statistically significant in the parallel trials (þ2%, 11 s, P ¼ 0.24).
Comparison of a calcium antagonist to its combination with a b-blocker (CA þ BB) Time to 1 mm ST-segment depression Time to 1 mm ST-segment depression was available in 399 patients treated by monotherapy and 388 patients receiving combined treatment. Time to 1 mm ST-segment depression was 9% (41 s, P o 0.001) higher with the combined therapy. A graphical display with 95% CIs is shown in Figure 1 . In the six trials with an exercise test performed within the 6 h following drug intake there was a statistically significant difference of 10% (46 s, P o 0.001), while there was no statistical difference (2%, 10 s, P ¼ 0.66) in the only trial where the exercise test was performed after 6 h [31] .
An estimation of the exercise duration was available for 338 patients treated by monotherapy and 330 patients treated by combined therapy. The total duration of exercise was 4% (17 s) higher with the combined therapy. However this difference was not statistically significant (P ¼ 0.35). A graphical display with 95% CIs is shown in Figure 2 .
Time to onset of pain
As far as patients remaining with angina during exercise testing are concerned, the difference in time to onset of pain was of borderline significance (Fig. 3) favouring the combination. The unadjusted mean difference was 9% (30 s, P ¼ 0.067).
Due to the small number of trials, short-and long-acting calcium antagonists could not be analysed separately.
The results of the secondary analysis performed independently on cross-over and parallel trials are not presented due to the small numbers of patients and of trials.
Discussion
This quantitative overview shows that, as far as exercise testing is concerned, the combination of a calcium antagonist and a b-blocker is more effective than a monotherapy by either drug alone. However, the difference in efficacy is rather small and might be limited to the 6 h following drug intake. The limited data on combination with nitrates did not allow a meta-analysis.
Combination therapy was significantly superior to monotherapy by a calcium antagonist only for time to 1 mm STsegment depression measured at peak. However, the number of studies was limited and there was a favourable trend in the three tested parameters.
Combined treatment was significantly superior to a bblocker alone, but this difference was only statistically significant when the exercise test was performed less than 6 h after drug administration. Although mean heart rate was not available after treatment in most of the trials, it appears unlikely that the transient benefit is due to suboptimal blockade since the prescribed doses were in general those recommended for angina pectoris.
Limitations of the study
The included trials did not allow the estimation of differences in rate-pressure product. However, regarding the relatively small magnitude of the effect on the three analysed exercise-test parameters it appears unlikely that a major effect on the rate-pressure product might be observed.
No direct comparison of BB þ CA and CA þ BB was performed. Nevertheless, the difference between combination therapy and monotherapy was similar, independent of whether the initial monotherapy was a calcium antagonist or a b-blocker except for total exercise duration where the difference was greater in the BB þ CA comparison. This minimal increase in total exercise duration might be explained by the reduced effort tolerance under treatment with b-blockers alone [33] [34] [35] being offset by the vasodilator action of calcium antagonists.
Besides, this meta-analysis did not allow the comparison of the efficacy of the association of a rate-slowing CA with BB and of the association of a dihydropyridine with BB.
Publication bias cannot be ruled out in the present report because only published data were selected [10] . However, because it is unlikely that trials with strong differences between treatments were not published, a publication bias underestimating treatment effects does not appear likely and if anything it rather might exist in the opposite direction (accordingly, the differences between treatments reported here are probably not underestimated). Furthermore, the present study was limited to the articles published before 2000. However, two recent publications seem to confirm the conclusion of this meta-analysis [36, 37] .
In only six trials were more than 100 patients randomized. Small trials with nominally significant P-values tend to overestimate the size of treatment effect, because the treatment effect must be large if statistical significance is to be reached with a small sample size [38] . Therefore, a meta-analysis that includes only small trials is more likely to overestimate treatment effects, leading to an overly favourable view of an agent's efficacy [39] . However, few of the included studies did demonstrate significant differences between monotherapy and combined therapy, suggesting that any such bias may be small. In addition, only English language articles were retrieved. Reports of randomized clinical trials with statistically positive results are more likely to be published in English than those with negative results [40] . Nevertheless, it has been established that language-restricted meta-analyses overestimate the treatment effect by only 2% compared with languageinclusive meta-analyses [10] .
Exercise testing is less sensitive and less specific in women than in men [4] . The included trials do not allow for comparison of the differences between combination therapy and monotherapy with respect to sex. However, since higher percentages of men were included in the selected trials, sex is an unlikely explanation for the relatively small differences observed between combination therapy and monotherapy.
To our surprise, it was not always specified whether two or more reproducible exercise tests were required before randomization, which may have led to higher variability. The impact of such an effect will be more likely on the SD than on the estimated mean. We were also unable to compare efficacy according to the severity of the disease or to total ischaemic burden because few data on ambulatory monitoring were available.
Besides, the diagnosis of chronic stable angina was not confirmed by coronary angiography or documented myocardial infarction in all trials and some patients with other pathology than chronic stable angina might have been included in some trials [1, 2] . This might have led to an underestimation of the treatment effect and a decrease in power.
Despite the fact that in addressing chronic stable angina the focus should be on the prevention and improvement of symptoms, the selected trials did not allow for performing a meta-analysis either on clinical data, on quality of life or on clinical events. Only one trial [6] reported data on the outcome in 682 patients followed up for 2 years and it showed an insignificant trend to a lower rate of hard endpoints in the group receiving combined therapy.
In the same way, no meta-analysis on safety data could be performed on the included trials when authors who had reservations on the usefulness of combined therapy underlined the risk of side-effects with combination therapy [41] [42] [43] [44] .
When searching the literature for the present meta-analysis we were surprised by the lack of published data on combination therapy with long-acting nitrates, particularly in view of their frequency of use. In a recent meta-analysis comparing different monotherapies in the treatment of chronic stable angina, only 12 trials comparing long-acting nitrates to calcium antagonists, six trials comparing longacting nitrates to b-blockers and one combination study were retrieved [5] .
Interpretation
It could be argued that comparison of combined therapy and monotherapy is of limited importance because many patients undergo interventional procedures. However, this is often not the case due to large differences in availability of such procedures between countries, but also in particular patient groups, for example, in the elderly (systematically excluded from these comparative studies) in whom multicoronary, calcified stenoses are present and the risks of surgical procedures are substantial. Moreover, many patients after interventions still remain on antianginal therapy. Whether or not these patients should be treated with monoterapy or polytherapy is still left to the non-evidence-based decision of the individual physician.
The absolute differences observed in this meta-analysis seem only slightly smaller than the usually published difference between b-blockers and placebo or calcium antagonists and placebo [45, 46] . However, because of the great heterogeneity in exercise-test protocols and in sample sizes only percentages and standardized mean differences are the parameters of choice. The observed difference in exercise performance between combined therapy and monotherapy is 4-12%.
Conclusion
In summary, this quantitative overview shows that, as far as exercise capacity is concerned, the combination of a calcium antagonist and a b-blocker is statistically more effective than a monotherapy. However, the difference seems restricted to the first 6 h following drug intake.
